Acurx Pharmaceuticals Inc

ACXP11 Dec 2024
Healthcare
$0.89
+0.05 (+4.97%)
Lowest Today
$0.85
Highest Today
$0.96
Today’s Open
$0.89
Prev. Close
$0.89
52 Week High
$5.28
52 Week Low
$0.72
To Invest in Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc

Healthcare
ACXP11 Dec 2024
+0.05 (+4.97%)
1M
3M
6M
1Y
5Y
Low
$0.85
Day’s Range
High
$0.96
0.85
52 Week Low
$0.72
52-Week Range
52 Week High
$5.28
0.72
1 Day
-
1 Week
+20.62%
1 month return
-49.72%
3 month return
-53.5%
6 month return
-62.65%
1 Year return
-73.42%
3 Years return
-77.5%
5 Years return
-
10 Years return
-
Institutional Holdings
Vanguard Group Inc
3.13
Vanguard Total Stock Mkt Idx Inv
2.27
Prospect Financial Services Llc
1.75
Geode Capital Management, LLC
0.87
Vanguard Institutional Extnd Mkt Idx Tr
0.86
Fidelity Extended Market Index
0.46
Morgan Stanley - Brokerage Accounts
0.27

Market Status

Fundamentals
Market Cap
14.95 mln
PB Ratio
4.76
PE Ratio
0
Enterprise Value
6.91 mln
Total Assets
7.71 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Organisation
Acurx Pharmaceuticals Inc
Employees
4
Industry
Biotechnology
CEO
Mr. David P. Luci CPA, Esq., J.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step